Most psychiatrists now agree that transcranial magnetic stimulation belongs alongside medication and psychotherapy as a core treatment option for depression — not as a last resort when everything else has failed. A 2025 consensus review from the American Psychiatric Association and UTHealth Houston formally described TMS as a “third pillar” of psychiatric treatment, signaling a meaningful shift in how the field thinks about brain stimulation. For the roughly 50 percent of depression patients who respond to TMS, with over 30 percent achieving full remission, this recognition is long overdue. Standard antidepressants, by comparison, showed a success rate of just 27.5 percent in the landmark NIMH-funded STAR*D trial — and that number drops sharply with each subsequent medication tried.
This does not mean TMS is universally better than medication. The choice between the two depends on the severity of illness, treatment history, cost, access, and individual biology. But the old clinical habit of exhausting three or four medications before even mentioning TMS is increasingly seen as outdated. A December 2025 opinion piece in Undark argued that TMS should not be reserved only for treatment-resistant cases and could be offered much earlier in treatment. This article walks through what the research actually shows about TMS versus medication — success rates, side effects, cost, insurance coverage, and what newer protocols like the Stanford SAINT method mean for patients who have struggled to find relief.
Table of Contents
- How Does TMS Compare to Medication for Depression, According to Psychiatrists?
- Side Effects and Safety — Where TMS and Antidepressants Diverge Sharply
- The Stanford SAINT Protocol — A Potential Game-Changer for Severe Depression
- What Does TMS Actually Cost, and Will Insurance Pay for It?
- Who Should Not Choose TMS — And When Medication Is the Better Call
- TMS for Adolescents and Younger Patients
- At-Home TMS and the Future of Brain Stimulation Treatment
- Conclusion
- Frequently Asked Questions
How Does TMS Compare to Medication for Depression, According to Psychiatrists?
The comparison starts with numbers, and the numbers favor TMS in several important ways. In treatment-resistant depression — meaning patients who have already failed at least one adequate medication trial — TMS is two to four times more effective at relieving depressive symptoms compared to trying yet another drug. The STAR*D trial remains the largest real-world study of antidepressant effectiveness, and its findings are sobering: by the time a patient reaches their fourth medication attempt, the success rate falls below 7 percent. TMS, meanwhile, maintains roughly a 50 percent response rate even in these harder-to-treat populations. Where medication still holds certain advantages is in accessibility and familiarity. A prescription can be filled at any pharmacy in the country.
TMS requires repeated visits to a clinic with specialized equipment — typically five sessions per week over four to six weeks for a standard course. For someone in a rural area or without reliable transportation, that logistics gap matters. Psychiatrists who advocate for earlier use of TMS are not dismissing medication entirely. They are arguing that the treatment sequence should be guided by evidence and patient preference rather than institutional inertia. The combination of TMS with psychotherapy has also shown promising results. Research indicates that pairing TMS with therapy produces a 55 percent remission rate, compared to 31 to 37 percent for TMS used alone. This suggests that TMS may work best not as a standalone fix but as part of a broader treatment plan — something psychiatrists increasingly emphasize when counseling patients about their options.
Side Effects and Safety — Where TMS and Antidepressants Diverge Sharply
One of the most consistent findings in the TMS literature is the near-absence of systemic side effects. TMS does not cause weight gain, sexual dysfunction, fatigue, gastrointestinal problems, or the emotional blunting that many patients report on SSRIs and SNRIs. The most common complaints are mild scalp discomfort or headache during or after treatment sessions, and the seizure risk is extremely low — roughly one per 30,000 treatments. Antidepressants, by contrast, carry a well-documented burden of side effects that frequently leads patients to stop taking them. Weight gain and sexual dysfunction are among the most commonly cited reasons for medication discontinuation, and these effects are not trivial.
A patient who gains 30 pounds on an SSRI or loses the ability to maintain intimate relationships faces a real quality-of-life tradeoff that can undermine the very recovery the medication is supposed to support. However, TMS is not without limitations on the safety front. Patients with metallic implants in or near the head, certain types of cochlear implants, or implanted stimulators cannot safely undergo TMS. People with a history of seizure disorders require careful evaluation. And while the side effect profile is mild for most, some patients find the sensation of repeated magnetic pulses uncomfortable enough to discontinue treatment. The tolerability advantage is real, but it is not universal.
The Stanford SAINT Protocol — A Potential Game-Changer for Severe Depression
The Stanford Accelerated Intelligent Neuromodulation Therapy protocol, known as SAINT, represents perhaps the most dramatic recent advance in TMS. FDA-cleared in September 2022, SAINT compresses the entire course of treatment into five days, delivering ten sessions per day rather than spreading treatment over four to six weeks. The initial Stanford study produced a 90 percent remission rate — 19 of 21 participants no longer met criteria for depression after five days of treatment. Sixty percent were still in remission one month later. A randomized controlled follow-up trial confirmed these results were not a fluke, showing a 78 percent remission rate with the active protocol compared to just 13 percent for sham treatment. For context, no antidepressant on the market comes close to these figures, particularly in treatment-resistant populations.
The accelerated timeline also addresses one of TMS’s practical disadvantages — the weeks of daily clinic visits that standard protocols require. The catch, at least for now, is availability. SAINT requires specialized equipment and expertise that not all TMS clinics have. Insurance coverage for accelerated protocols varies widely, and the out-of-pocket cost can be significant. Psychiatrists familiar with the data tend to be enthusiastic about SAINT’s potential, but most acknowledge that broader access will take time. Patients who are acutely suicidal or severely impaired may benefit most from the compressed timeline, but they are also the patients who face the greatest barriers to accessing specialized care.
What Does TMS Actually Cost, and Will Insurance Pay for It?
Cost remains one of the most practical barriers to TMS treatment. A single session typically runs between $300 and $500, and a full course of treatment without insurance ranges from $6,000 to $15,000. For many patients, that is a prohibitive number — especially when a month’s supply of generic sertraline costs under $20 with insurance. The insurance landscape, however, is shifting in TMS’s favor. Medicare now covers TMS for severe major depressive disorder, providing up to six weeks of treatment with a 20 percent coinsurance requirement. In a notable move, Cigna and its parent company Evernorth eliminated prior authorization requirements for TMS effective March 6, 2026, removing one of the most frustrating administrative hurdles patients and providers faced.
Major insurers including UnitedHealthcare, Aetna, Cigna, and Tricare now also cover TMS for adolescents aged 15 to 17, reflecting the FDA’s expanded approval for that age group. The tradeoff calculation is worth examining honestly. Antidepressants are cheaper per month, but many patients take them for years or even decades. The cumulative cost — financial and physical — of long-term medication use is rarely discussed upfront. TMS, while expensive in the short term, offers the possibility of sustained remission without ongoing treatment costs. For patients with good insurance coverage, the financial gap between the two options has narrowed considerably.
Who Should Not Choose TMS — And When Medication Is the Better Call
TMS is not the right answer for everyone, and responsible psychiatrists are clear about its limitations. Patients with mild depression that has never been treated with any intervention should generally start with psychotherapy, medication, or both. The strongest evidence for TMS exists in the treatment-resistant space — people who have already tried and failed at least one adequate medication trial. There are also conditions where TMS has limited or no evidence of benefit. While the FDA has cleared TMS for major depressive disorder, OCD, smoking cessation, anxious depression, and PTSD, it has not been approved for conditions like bipolar depression, schizophrenia, or dementia-related behavioral symptoms — though research in some of these areas is ongoing.
Patients sometimes arrive at TMS clinics expecting it to address problems it was not designed to solve, and managing those expectations is an important part of clinical practice. Medication also has the advantage of continuous coverage. An SSRI taken daily provides around-the-clock modulation of serotonin activity. TMS sessions are intermittent, and while the neuroplastic changes they produce can be lasting, some patients do experience symptom recurrence and need maintenance treatments. Psychiatrists increasingly recommend an integrated approach — using TMS to achieve remission and then considering low-dose medication or periodic TMS booster sessions to maintain it.
TMS for Adolescents and Younger Patients
The FDA’s expansion of TMS approval to include adolescents aged 15 and older reflects growing concern about the effects of long-term antidepressant use in developing brains. SSRIs carry a black-box warning about increased suicidality risk in young people, and many parents and clinicians are understandably cautious about starting a teenager on medication that may need to be taken for years. TMS offers an alternative that avoids systemic drug exposure entirely. Insurance coverage for adolescent TMS has expanded alongside the FDA clearance.
UnitedHealthcare, Aetna, Cigna, and Tricare all now cover TMS for patients aged 15 to 17, which removes a significant financial barrier. However, the research base in adolescents is still smaller than in adults, and clinicians generally recommend careful patient selection and close monitoring. A teenager with severe, treatment-resistant depression and intolerable medication side effects is a strong candidate. A teenager with mild symptoms and no prior treatment history probably is not.
At-Home TMS and the Future of Brain Stimulation Treatment
The treatment landscape is likely to shift again in the near future. Flow Neuroscience received FDA approval for its FL-100 at-home TMS device, with a planned U.S. launch in the second quarter of 2026 at a retail price between $500 and $800. If the device proves effective in real-world use, it could fundamentally change the accessibility equation — eliminating the need for daily clinic visits and reducing the total cost of treatment by an order of magnitude.
Psychiatric News published a 2025 special report titled “12 Notes About TMS,” emphasizing that the technology has advanced significantly in precision, protocols, and clinical application. The field is moving toward personalized targeting — using brain imaging to identify the exact cortical region most likely to respond in each individual patient — and shorter, more intensive treatment courses. For patients navigating depression treatment today, the practical takeaway is that TMS is no longer an experimental curiosity or a desperation measure. It is a mainstream treatment with a growing evidence base, expanding insurance coverage, and improving technology.
Conclusion
The psychiatric consensus in 2025 and 2026 is clear: TMS deserves consideration as a frontline treatment option, not merely as a fallback after multiple medication failures. The data support its effectiveness — particularly the roughly 50 percent response rate that holds up even in treatment-resistant populations, the dramatically better side effect profile compared to antidepressants, and emerging protocols like SAINT that can achieve remission in days rather than months. Insurance barriers are falling, adolescent access is expanding, and at-home devices may soon make the treatment available to millions of people who currently cannot access it. For anyone weighing TMS against medication, the most important step is an honest conversation with a psychiatrist who is familiar with both options.
Neither treatment is perfect. Medication is cheaper, more accessible, and works continuously. TMS avoids systemic side effects and may produce more durable remission in certain patients. The best outcomes often come from combining approaches — using TMS alongside psychotherapy and, in some cases, lower doses of medication. The old model of trying drug after drug until something works is giving way to a more nuanced, evidence-based approach, and patients are better served for it.
Frequently Asked Questions
Is TMS painful?
Most patients describe the sensation as a tapping or clicking on the scalp. Mild discomfort or headache is the most common side effect. The procedure does not require anesthesia, and patients can drive themselves home afterward. Some people find the sensation unpleasant at first but adjust within the first few sessions.
How long do the effects of TMS last?
Many patients experience sustained remission lasting several months to a year or more after a full course of treatment. Some patients benefit from periodic maintenance sessions. The Stanford SAINT protocol showed 60 percent of participants remained in remission one month after the five-day treatment, though longer-term follow-up data is still being collected.
Can I take antidepressants while doing TMS?
Yes. Many patients undergo TMS while continuing their current medication regimen. Some psychiatrists will later taper medication once TMS has taken effect. TMS combined with psychotherapy has shown a 55 percent remission rate, suggesting that integrated treatment plans often outperform any single approach.
Does insurance cover TMS?
Coverage has expanded significantly. Medicare covers TMS for severe major depressive disorder, and major commercial insurers including UnitedHealthcare, Aetna, Cigna, and Tricare now provide coverage. Cigna eliminated prior authorization requirements for TMS in March 2026. Coverage for adolescents aged 15 to 17 is also increasingly available.
Is TMS FDA-approved for conditions other than depression?
Yes. The FDA has cleared TMS for obsessive-compulsive disorder, smoking cessation, anxious depression, and PTSD, in addition to major depressive disorder in adults and adolescents aged 15 and older.
How is TMS different from electroconvulsive therapy (ECT)?
TMS and ECT are fundamentally different procedures. ECT requires general anesthesia, induces a controlled seizure, and can cause memory loss. TMS is performed while the patient is awake, uses focused magnetic pulses rather than electrical current, does not induce seizures under normal circumstances, and has no cognitive side effects. TMS is less invasive but is also generally considered less potent than ECT for the most severe, refractory cases.
